HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Ruelle, Jean ^a   Debaisieux, Laurent ^b   Vancutsem, Ellen ^c   De Bel, Annelies ^c   Delforge, Marie Luce ^b   Piérard, Denis ^c   Goubau, Patrick ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Assay variability; Blip; HIV 1 RNA; Residual viraemia; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; DILUTION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

DRUG MONITORING; HIV INFECTIONS; HIV-1; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 84862175772     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-100     Document Type: Article

References (20)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 239, 1. Department of Health and Human Services, http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf , Panel on Antiretroviral Guidelines for Adults and Adolescents.
2. European AIDS Clinical Society Guidelines Version 6.0. [http://www.eacs.eu].
3. Cohen C. Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen. HIV Clin Trials 2009, 10:116-124. 10.1310/hct1002-116, 19487182.
4. Protocols for Determination of Limits of Detection and Limits of Quantification. In Approved guideline NCCLS document EP17-A. NCCLS Wayne, Pennsylvania 2004,
5. Paba P, Fabeni L, Ciccozzi M, Perno CF, Ciotti M. Performance evaluation of the COBAS/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low viral load: a comparative study. J Virol Methods 2011, 173:399-402. 10.1016/j.jviromet.2011.03.014, 21419171.
6. Yan CS, Hanafi I, Kelleher AD, Carr AD, Amin J, McNally LP, Cunningham PH. Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification. J Clin Virol 2010, 49:249-253. 10.1016/j.jcv.2010.08.016, 20884287.
7. Pozniak A, Gupta RK, Pillay D, Arribas J, Hill A. Causes and consequences of incomplete HIV RNA suppression in clinical trials. HIV Clin Trials 2009, 10:289-298. 10.1310/hct1005-289, 19906623.
8. Mavigner M, Delobel P, Cazabat M, Dubois M, LFaqihi-Olive FE, Raymond S, Pasquier C, Marchou B, Massip P, Izopet J. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 2009, 4:e7658. 10.1371/journal.pone.0007658, 2765414, 19876401.
9. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010, 7:8.
10. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011, 203:960-968. 10.1093/infdis/jiq138, 3068029, 21402547.
11. Rosso R, Di Biagio A, Maggiolo F, Nulvesu L, Callegaro AP, Taramasso L, Bruzzone B, Viscoli C. Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. AIDS Care 2011, 24:54-58.
12. Haim-Boukobza S, Morand-Joubert L, Flandre P, Valin N, Fourati S, Sayon S, Lavignon M, Simon A, Girard PM, Katlama C, et al. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. AIDS 2011, 25:341-344. 10.1097/QAD.0b013e3283427de3, 21157295.
13. Widdrington J, Payne B, Medhi M, Valappil M, Schmid ML. The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART. J Infect 2011, 62:87-92. 10.1016/j.jinf.2010.11.001, 21073896.
14. Gianotti N, Galli L, Racca S, Salpietro S, Cossarini F, Spagnuolo V, Barda B, Canducci F, Clementi M, Lazzarin A, Castagna A. Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. J Antimicrob Chemother 2011, 67:213-217.
15. Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T, Pandori M, Havlir DV, Wong JK. Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. J Virol Methods 2011, 175:261-265. 10.1016/j.jviromet.2011.04.015, 21536073.
16. Amendola A, Bloisi M, Marsella P, Sabatini R, Bibbo A, Angeletti C, Capobianchi MR. Standardization and performance evaluation of modified and ultrasensitive versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia. J Clin Virol 2011, 52:17-22. 10.1016/j.jcv.2011.04.012, 21764631.
17. Anderson JA, Archin NM, Ince W, Parker D, Wiegand A, Coffin JM, Kuruc J, Eron J, Swanstrom R, Margolis DM. Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J Virol 2011, 85:5220-5223. 10.1128/JVI.00284-11, 3126162, 21367910.
18. Mens H, Kearney M, Wiegand A, Spindler J, Maldarelli F, Mellors JW, Coffin JM. Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays. J Vis Exp 2011, 55:e2960.
19. Verhofstede C, Van Wanzeele F, Reynaerts J, Mangelschots M, Plum J, Fransen K. Viral load assay sensitivity and low level viremia in HAART treated HIV patients. J Clin Virol 2010, 47:335-339. 10.1016/j.jcv.2010.01.008, 20138803.
20. Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011, 204:135-138. 10.1093/infdis/jir208, 3105034, 21628667.